Basic Information
| LncRNA/CircRNA Name | DANCR |
| Synonyms | DANCR, AGU2, ANCR, KIAA0114, SNHG13, lncRNA-ANCR |
| Region | GRCh38_4:52712404-52720351 |
| Ensemble | ENSG00000226950 |
| Refseq | NR_024031 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | malignant glioma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, Luciferase reporter assays, in vitro knockdown etc. |
| Sample | cell lines (U87MG, U251MG, LN18,U138MG) |
| Expression Pattern | up-regulated |
| Function Description | Long noncoding RNA DANCR mediates cisplatin resistance in glioma cells via activating AXL/PI3K/Akt/NF-kB signaling pathway. DNACR also attenuated cisplatin-induced cell apoptosis in vitro and in vivo. DANCR upregulated AXL via competitively binding miR-33a-5p, miR-33b-5p, miR-1-3p, miR-206, and miR-613. Through upregulating AXL, DANCR activated PI3K/Akt/NF-kB signaling pathway in glioma cells. Inhibiting AXL/PI3K/Akt/NF-kB signaling pathway reversed the effects of DANCR on cisplatin resistance.DANCR promotes cisplatin resistance via activating AXL/PI3K/Akt/NF-kB signaling pathway in glioma.DANCR would be a potential biomarker for predicting cisplatin sensitivity and a therapeutic target for enhancing cisplatin efficacy in glioma. |
| Pubmed ID | 29572052 |
| Year | 2018 |
| Title | Long noncoding RNA DANCR mediates cisplatin resistance in glioma cells via activating AXL/PI3K/Akt/NF-kB signaling pathway. |
External Links
| Links for DANCR | GenBank HGNC NONCODE |
| Links for malignant glioma | OMIM COSMIC |